Harrow (HROW) Competitors $31.23 -0.53 (-1.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$31.85 +0.62 (+1.99%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. LNTH, AXSM, TLX, PCVX, MRUS, KRYS, CYTK, ZLAB, ADMA, and ABVXShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Lantheus (LNTH), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), Merus (MRUS), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), ADMA Biologics (ADMA), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors Lantheus Axsome Therapeutics Telix Pharmaceuticals Vaxcyte Merus Krystal Biotech Cytokinetics Zai Lab ADMA Biologics Abivax Harrow (NASDAQ:HROW) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Do institutionals & insiders hold more shares of HROW or LNTH? 72.8% of Harrow shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 1.5% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, HROW or LNTH? Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Does the media prefer HROW or LNTH? In the previous week, Lantheus had 13 more articles in the media than Harrow. MarketBeat recorded 20 mentions for Lantheus and 7 mentions for Harrow. Lantheus' average media sentiment score of 0.91 beat Harrow's score of 0.36 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HROW or LNTH more profitable? Lantheus has a net margin of 16.55% compared to Harrow's net margin of -10.19%. Lantheus' return on equity of 36.99% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-10.19% -25.01% -4.27% Lantheus 16.55%36.99%20.55% Which has preferable valuation & earnings, HROW or LNTH? Lantheus has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M5.74-$17.48M-$0.56-55.77Lantheus$1.53B3.18$312.44M$3.5220.05 Do analysts rate HROW or LNTH? Harrow currently has a consensus price target of $63.83, suggesting a potential upside of 104.40%. Lantheus has a consensus price target of $131.20, suggesting a potential upside of 85.91%. Given Harrow's stronger consensus rating and higher probable upside, research analysts plainly believe Harrow is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryLantheus beats Harrow on 10 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.17B$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-55.778.9728.7823.81Price / Sales5.74437.65372.2066.04Price / Cash232.26157.7635.4557.96Price / Book16.024.838.275.54Net Income-$17.48M$31.62M$3.25B$259.28M7 Day Performance-13.71%-5.28%-3.70%-4.64%1 Month Performance2.16%4.38%4.34%4.41%1 Year Performance32.33%-2.49%25.90%17.95% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.5184 of 5 stars$31.23-1.7%$63.83+104.4%+27.2%$1.17B$199.61M-55.77180Upcoming EarningsLNTHLantheus4.6193 of 5 stars$72.41-0.7%$131.20+81.2%-28.4%$5.01B$1.54B20.57700News CoverageUpcoming EarningsAnalyst RevisionAXSMAxsome Therapeutics4.8236 of 5 stars$100.39-0.4%$172.33+71.7%+19.8%$4.94B$432.16M-17.40380Positive NewsUpcoming EarningsTLXTelix PharmaceuticalsN/A$13.96-1.7%$22.33+60.0%N/A$4.72B$516.72M0.00N/AGap DownHigh Trading VolumePCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.63BN/A-8.99160News CoveragePositive NewsUpcoming EarningsMRUSMerus2.9208 of 5 stars$65.59-1.8%$86.40+31.7%+25.1%$4.54B$54.73M-16.0837News CoverageUpcoming EarningsKRYSKrystal Biotech4.8923 of 5 stars$152.91+3.6%$211.33+38.2%-21.0%$4.42B$333.45M36.76210Upcoming EarningsCYTKCytokinetics4.0943 of 5 stars$36.63-1.5%$70.92+93.6%-36.6%$4.37B$18.47M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeZLABZai Lab2.217 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.30B$418.33M-15.541,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap UpADMAADMA Biologics4.289 of 5 stars$18.00-0.1%$27.67+53.7%+57.7%$4.30B$459.38M21.18530Upcoming EarningsABVXAbivax3.6049 of 5 stars$66.57+0.1%$80.00+20.2%+511.7%$4.23BN/A0.0061News CoverageAnalyst ForecastGap DownHigh Trading Volume Related Companies and Tools Related Companies Lantheus Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives Vaxcyte Alternatives Merus Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Zai Lab Alternatives ADMA Biologics Alternatives Abivax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
